NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Bio-Techne Corporation (TECH) Stock Analysis

Bio-Techne Corporation (TECH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TECH

$72.43

−$0.02 (−0.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TECH with… →

TECH Key Statistics

As of Sep 4, 2026
Trading
Open
$72.40
Previous Close
$72.45
Day's Range
72.40–72.48
52-Week Range
43.20–72.62
Volume
1.86M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.27
Valuation
Market Cap
$11.36B
P/E Ratio
62.44
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
31.40
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.10
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.35
EPS (ttm)Profit attributable to each share over the last twelve months.
1.16
Financials (FY)
Revenue (FY)
$1.22B+5.23%
Net Income (FY)
$73.40M−56.34%
Profit marginThe share of revenue left as profit after all costs and taxes.
14.97%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
156.82M
1-Year Return
+37.64%
Dividend and dates
Dividend
$0.32+0.44%
Ex-Dividend Date
August 24, 2026
Earnings Date
November 9, 2026estimated
Avg Volume
4.76M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TECH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+23.69%
2025−17.89%
2024−6.25%
2023−6.49%
2022−35.69%
2021+63.40%
2020+45.40%
2019+52.67%
2018+12.61%
2017+27.40%
2016 (partial year)−7.37%

As of September 4, 2026.

TECH Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$1.22B$73.40M6.0%
2024$1.16B$168.11M14.5%
2023$1.14B$285.26M25.1%
2022$1.11B$272.05M24.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.22B$790.27M$242.80M$73.40M6.0%
2024$1.16B$769.73M$246.40M$168.11M14.5%
2023$1.14B$769.82M$291.00M$285.26M25.1%
2022$1.11B$756.50M$295.83M$272.05M24.6%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

TECH Dividend History

$0.32+0.0% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.243—
2025$0.324+0.0%
2024$0.324+0.0%
2023$0.324+0.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.243—
2025$0.324+0.0%
2024$0.324+0.0%
2023$0.324+0.0%
2022$0.324+0.0%
2021$0.324+0.0%
2020$0.324+0.0%
2019$0.324+0.0%
2018$0.324+0.0%
2017$0.324+300.0%
2016$0.081—

Most recent payment: $0.08 per share, ex-dividend August 24, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

TECH Valuation vs Biotechnology Median

Median of 656 stocks
MetricTECHBiotechnology medianvs median
P/E62.4412.575.0x the median
P/S ratio9.3515.2639% below
Profit margin14.97%0.00%15.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bio-Techne Corporation (TECH) is capitalised at $11.36B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3,000.

TECH last closed at $72.43 on September 4, 2026. That is −$0.02 (−0.03%) against the previous close. Over the past 52 weeks the price has ranged from $43.20 to $72.62. The latest close sits 67.66% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.22B. Against the prior fiscal year total of $1.16B, that is a change of +5.23%. The same year closed with net income of $73.40M. That is −56.34% against the prior fiscal year. Profit margin runs at 14.97%. That is 15 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 1.16.

Across the 4 fiscal years on file, revenue moves from $1.11B in 2022 to $1.22B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 62.44. That is 5 times the Biotechnology median of 12.57. On forward earnings the ratio is 31.4. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.1. Measured against sales, the shares trade at 9.35 times revenue. On price-to-sales that is 38.76% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +37.64%. Across 10 years the annualized return works out at +11.14%. Beta against the wider market is reported at 1.28. Annualized volatility over the trailing 10 years is 34.54%.

Growth & Income

Shareholders receive a dividend, yielding 0.44% on the latest price. That is 1 percentage points below the Biotechnology median yield of 1.47%. At the indicated rate that is $0.32 a share a year. The ex-dividend date on file is August 24, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $0.24 a share. The year before, 2025, totalled $0.32 a share.

2026 is still running; the price is +23.69% year to date. Across the complete calendar years on file, 2021 returned +63.40% and 2022 returned −35.69%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Bio-Techne Corporation (TECH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bio-Techne Corporation TECH $11.36B 62.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Bio-Techne Corporation trades at a P/E of 62.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Visit website →